Kalpana Kalpana (Editor)

Inotuzumab ozogamicin

Updated on
Edit
Like
Comment
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Type
  
Whole antibody

Target
  
CD22

CAS Number
  
635715-01-4

Molar mass
  
150,000 g/mol

Source
  
Humanized (from mouse)

ATC code
  
L01XC26 (WHO)

ChemSpider
  
none

Inotuzumab ozogamicin Full text Profile of inotuzumab ozogamicin and its potential in the

The mechanism of action of inotuzumab ozogamicin


Inotuzumab ozogamicin (CMC-544) is an antibody-drug conjugate for the treatment of cancers. It consists of the humanized monoclonal antibody inotuzumab (for CD22), linked to a cytotoxic agent from the class of calicheamicins (which is reflected by 'ozogamicin' in the drug's name).

Contents

Inotuzumab ozogamicin Full text Profile of inotuzumab ozogamicin and its potential in the

This drug is being developed by Pfizer and UCB.

It has undergone numerous clinical trials, including two phase II trials for Non-Hodgkin lymphoma (NHL).

A Phase III trial in patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma (NHL) who were not candidates for intensive high-dose chemotherapy was terminated for futility.

Inotuzumab ozogamicin Inotuzumab ozogamicin CMC544 Drug Description ADC Review ADC Review

As of April 2016 ten clinical trials were active (including one phase III for Acute Lymphoblastic Leukemia (ALL)), six still recruiting.

Inotuzumab ozogamicin FDA grants breakthrough status for Pfizer39s leukaemia drug

Side effects of inotuzumab ozogamicin


Inotuzumab ozogamicin A Stathis Lymphomas New drugs in the treatment of lymphomas

Inotuzumab ozogamicin 75

Inotuzumab ozogamicin Inotuzumab Ozogamicin in ALL Oncology Clinical Care Options

Inotuzumab ozogamicin FDA grants breakthrough status for Pfizer39s leukaemia drug

Inotuzumab ozogamicin Inotuzumab Ozogamicin Biology and Clinical Gary Schiller MD

Inotuzumab ozogamicin Investigational Immunotherapeutics for Precursor BCell ALL

References

Inotuzumab ozogamicin Wikipedia
(Text) CC BY-SA